Board meeting on October 08, 2026 to consider fund-raise via rights issue of equity shares
The company has informed BSE that a meeting of its Board of Directors is scheduled for Thursday, October 08, 2026.
- Board Meeting Date
- Thursday, October 08, 2026
- Item to be Considered
- raising of funds through the issuance of equity shares of face value ₹ 5 each, by way of a rights issue to eligible equity shareholders
- Trading Window Closed From
- October 01, 2026
- Trading Window Closed Till
- November 05, 2026
- Status of Proposal
- a proposal being placed before the Board, not an approval
What is being considered
The company has informed the exchange that a meeting of its Board of Directors is scheduled to be held on Thursday, October 08, 2026. Among the matters to be considered is the raising of funds through the issuance of equity shares of the company with a face value of ₹ 5 each, by way of a rights issue to its eligible equity shareholders.
The operative word is consider. The Board is yet to take a decision on the fund-raise.
Key points from the intimation
- Route: a rights issue, meaning shares offered to eligible equity shareholders.
- Instrument: equity shares of face value ₹ 5 each.
- Terms and conditions: to be determined by the Board.
- Condition: the proposed fund-raise is subject to receipt of all necessary regulatory, statutory and other applicable approvals.
Trading window
- The trading window for dealing in the securities of the company by Designated Persons, Insiders, Connected Persons and their immediate relatives is closed with effect from October 01, 2026.
- It remains closed till 48 hours after the disclosure of the unaudited financial results for the quarter and nine months ended September 30, 2026, i.e. till November 05, 2026.
- As the Board meeting falls within this already closed period, no separate trading window has been closed for it.
How to read this
A rights issue is a way for a company to raise money from its existing shareholders, typically in proportion to their current holding. Because new shares are issued, the eventual impact on existing shareholders depends on the terms the Board determines, such as the price, the ratio and the size of the issue, along with the purpose the funds are put to.
At this stage, this is prior intimation of a proposal being placed before the Board. The outcome of the meeting, including the terms if approved, would carry the details investors would need to assess the impact.
Also from Novartis India
CARE A; Stable assigned to Evonile Pharma's long-term bank facilities, CARE A2+ for short-term
7 Oct 2026
Name changed to Evonile Pharma Limited with effect from October 01, 2026; fresh Certificate of Incorporation issued
1 Oct 2026
Company name changed from Novartis India Limited to Evonile Pharma Limited with effect from October 01, 2026
1 Oct 2026
More numbers
- Face value of equity shares proposed to be issued₹ 5
- Period after results disclosure till which trading window stays closed48 hours
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.